IBIO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 22:42):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
Dzisiejszy wolumen	138 633
Średni wolumen	3.96M
Kapitalizacja rynkowa	15.68M
EPS	$0 ( 2024-02-13 )
Następna data zysków	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0150 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Duran Felipe	Buy	35 800	Stock Option (right to buy)
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock

INSIDER POWER
85.79
Last 90 transactions
Buy: 50 021 245 \| Sell: 29 398 433

Wolumen Korelacja

Długi: 0.14 (neutral)

Krótki: -0.66 (moderate negative)

Signal:(45.046) Neutral

Ibio Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ibio Inc Korelacja - Waluta/Towar

0.79
( moderate )

0.87
( strong )

0.51
( weak )

-0.54
( weak negative )

-0.92
( very strong negative )

Ibio Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2023
Przychody:	$0
Zysk brutto:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2022
Przychody:	$2.38M
Zysk brutto:	$2.17M (90.94 %)
EPS:	$-2 924.26

FY	2021
Przychody:	$2.37M
Zysk brutto:	$909 000 (38.34 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.